1859: Funding, Investors & Team (Sep 2026)
1859 is a biotechnology company focusing on the discovery and development of next-generation therapeutics. The company was founded in 2019 and is headquartered in San Diego, California.
1859 has raised $2.0M across 1 funding round on record, the most recent a Debt Financing of $2.0M announced in Oct 2021.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
1859 Company Profile and Key Stats
Latest funding round on record: Oct 2021.
1859 Funding Rounds
1859 Founders and Leadership Team
No contact details are on record for this team yet.
1859 Funding Compared to Other Biotechnology Startups
1859's latest round of $2.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like 1859 in Biotechnology and San Diego
Companies Similar to 1859
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
1859 Funding FAQs
What does 1859 do?
1859 is a biotechnology company focusing on the discovery and development of next-generation therapeutics. The company was founded in 2019 and is headquartered in San Diego, California.
How much funding has 1859 raised?
1859 has raised $2.0M across 1 round on record. The most recent is a Debt Financing of $2.0M announced in Oct 2021.
When did 1859 last raise funding?
1859's most recent funding round on record is a Debt Financing of $2.0M, announced in Oct 2021.
Who is the CEO of 1859?
Devon Cayer is listed as CEO at 1859.
Where is 1859 headquartered?
1859 is based in San Diego, California, United States.
How many employees does 1859 have?
1859 is in the 11-50 employee band.
How does 1859's funding compare to other Biotechnology startups?
1859's latest round of $2.0M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's 1859 Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for 1859 is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.